Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 19 Dec 2016 According to a Gradalis media release, status changed from active, no longer recruiting to completed.
- 20 Mar 2013 Planned End Date changed from 1 May 2012 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 20 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.